Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline
October 04 2020 - 6:39PM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today
announced it will host a R&D Day conference call and
simultaneous webcast on October 13th, 2020 focusing on its
comprehensive multi-modal approach to COVID-19.
During this 90-minute event, management will
highlight continued strategic advancement, challenges, key pipeline
updates and drivers of future growth in the COVID-19 space. Thirty
minutes will be reserved for analyst questions. The audio webcast
and transcript will be available on the Sorrento website for 30
days following the event.
Participants will include:Dr.
Henry Ji, Chairman and CEODr. Mike Royal, Chief Medical OfficerDr.
Mark Brunswick, SVP and Head of Regulatory and QualityDr. Robert
Allen, SVP and Antiviral and Oncolytic Immunotherapy DevelopmentDr.
Alexis Nahama, SVP of Corporate Development and Head of Diagnostics
and Pain ManagementBrian Cooley, SVP of Devices and Diagnostics
Bill Farley, VP of Business and Corporate Development
R&D Day
Agenda:
- Clinical
Stage Products (cleared Phase 1
or Phase 2)
- STI-1499 (COVI-GUARDTM neutralizing
antibody (nAb) against SARS-CoV-2 and its D614G Variant)
- STI-5656 (Abivertinib for reducing
cytokine storm and associated ARDS: acute respiratory distress
syndrome)
- Pre-Clinical Stage Products of high interest
- STI-2020 (COVI-AMGTM: affinity matured STI-1499 nAb)
- COVI-SHIELDTM: Additional potent nAb discovered and bi-specific
nAbs under evaluation
- STI-2030 (Salicyn-30: a novel, orally available, small molecule
inhibitor against SARS-CoV-2 infection with differentiated Mode of
Action with potential for pan-coronaviruses, is discovered and
selected for IND-enabling studies)
- STI-4398 (COVIDTRAP™: ACE2 receptor decoy protein) and its
bi-specific format with STI-2020
- STI-3333 (T-VIVA-19™: protein-based vaccines)
- STI-2099 (encoded plasmid DNA expressing STI-2020 nAb for
intra-muscular administration)
- Diagnostics
- COVI-TRACKTM: IgG/IgM Antibody Test
- COVI-STIXTM: Viral Antigen Test
- COVI-TRACETM: HP-LAMP Molecular Detection Test
“Early this year, when we pivoted into COVID-19 product
discovery and development, we decided to leverage our innovative
therapeutic technology platforms, know-how and state-of-the-art GMP
manufacturing capabilities to address COVID-19 from multiple and
different angles,” stated Dr. Henry Ji, Chairman and CEO for
Sorrento Therapeutics. “We have built during the last few months
one of the most comprehensive product pipelines for the COVID-19
continuum of care with incredible potential. We are looking forward
to updating our investors and the scientific community about our
progress to date.”
More information about the call-in number and how to access the
conference will be shared on the Sorrento website
(www.sorrentotherapeutics.com) in the upcoming days.
About Sorrento Therapeutics, Inc. Sorrento
is a clinical stage, antibody-centric, biopharmaceutical company
developing new therapies to treat cancers and COVID-19. Sorrento's
multimodal, multipronged approach to fighting cancer is made
possible by its extensive immuno-oncology platforms, including key
assets such as fully human antibodies ("G-MAB™ library"), clinical
stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug
conjugates ("ADCs"), and clinical stage oncolytic virus
("Seprehvir®", “Seprehvec™”). Sorrento is also developing potential
antiviral therapies and vaccines against coronaviruses, including
COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™,
COVI-AMG™ and T-VIVA-19™; and diagnostic test solutions, including
COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine
topical system) 1.8% for the treatment of post-herpetic neuralgia.
RTX has completed a phase 1B trial for intractable pain associated
with cancer and a phase 1B trial in osteoarthritis patients.
ZTlido® was approved by the FDA on February 28, 2018.
For more information, visit
www.sorrentotherapeutics.com
Forward-Looking StatementsThis
press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc., under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding Sorrento’s pipeline and
plans with respect to its clinical and pre-clinical COVID-19
programs, its COVID-19 therapeutic and diagnostic product
candidates and pipeline goals, and its proprietary technology
platforms and GMP manufacturing capabilities. Risks and
uncertainties that could cause our actual results to differ
materially and adversely from those expressed in our
forward-looking statements, include, but are not limited to: risks
related to Sorrento’s and its subsidiaries’, affiliates’ and
partners’ technologies and prospects and collaborations, including,
but not limited to clinical development risks, including risks in
the progress, timing, cost, and results of clinical trials and
product development programs; risk of difficulties or delays in
obtaining regulatory approvals; risks that clinical study results
may not meet any or all endpoints of a clinical study and that any
data generated from such studies may not support a regulatory
submission or approval; risks that prior test, study and trial
results may not be replicated in future studies and trials; risks
of manufacturing and supplying drug product; risks related to
leveraging the expertise of its employees, subsidiaries, affiliates
and partners to assist the company in the execution of its
therapeutic and diagnostic product candidates’ strategies; risks
related to the global impact of COVID-19; and other risks that are
described in Sorrento’s most recent periodic reports filed with the
Securities and Exchange Commission, including Sorrento’s Annual
Report on Form 10-K for the year ended December 31, 2019, and
subsequent Quarterly Reports on Form 10-Q filed with the Securities
and Exchange Commission, including the risk factors set forth in
those filings. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this release, and we undertake no obligation to update any
forward-looking statement in this press release except as required
by law.
ContactAlexis Nahama, DVM (SVP
Corporate Development)Email:
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered
trademarks of Sorrento Therapeutics, Inc.G-MAB™, COVI-GUARDTM,
COVI-SHIELD™, COVI-AMG™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™,
ACE-MABTM, COVI-TRACK™, COVI-STIX™ and COVI-TRACE™ are trademarks
of Sorrento Therapeutics, Inc.
ZTlido® is a trademark owned by Scilex
Pharmaceuticals Inc.All other trademarks are the property of their
respective owners. © 2020 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024